Analysts: Actavis-Allergan deal could create a marketing superpower

Valeant's ($VRX) been pursing Allergan ($AGN) for months now, but the California-based drugmaker may soon have another bid, too. Actavis ($ACT) is reportedly preparing to take its second stab at an Allergan deal, which could give Allergan some options. While the two potential transactions look comparable to Leerink Partners analysts Jason Gerberry and Seamus Fernandez from an accretion standpoint, the pair sees "less risk to Allergan brands suffering through the consolidation process" if Allergan combines with Actavis. Such a move "would unite two of the best marketing organizations in pharma," they wrote in a Wednesday note to shareholders. More

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.